{"id":1014,"date":"2026-03-02T20:27:27","date_gmt":"2026-03-02T20:27:27","guid":{"rendered":"https:\/\/rheumanext.pl\/?page_id=1014"},"modified":"2026-03-02T21:16:40","modified_gmt":"2026-03-02T21:16:40","slug":"celowane","status":"publish","type":"page","link":"https:\/\/rheumanext.pl\/pl\/kalkulatory\/leczenie\/celowane\/","title":{"rendered":"Leki celowane (tsDMARD)"},"content":{"rendered":"\n<p>Monitorowanie bezpiecze\u0144stwa i bada\u0144 kontrolnych przy lekach celowanych (w tym inhibitory JAK).<\/p>\n\n\n\n<p>Narz\u0119dzie wspieraj\u0105ce i edukacyjne. Nie zast\u0119puje decyzji klinicznych. <a href=\"https:\/\/rheumanext.pl\/bezpieczenstwo\/\" data-type=\"page\" data-id=\"832\">Zobacz zasady bezpiecze\u0144stwa.<\/a><\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Lista lek\u00f3w i checklisty<\/h2>\n\n\n<nav class=\"rn-calc-list wp-block-navigation is-layout-flex wp-block-navigation-is-layout-flex\" aria-label=\"Leczenie - celowane\"><ul class=\"wp-block-navigation__container  rn-calc-list wp-block-navigation\"><li class=\" wp-block-navigation-item wp-block-navigation-link\"><a class=\"wp-block-navigation-item__content\"  href=\"https:\/\/rheumanext.pl\/pl\/leki-innowacyjne-inhibitory-kinaz-janusowych-jak-tofacytynib-barycytynib-upadacytynib-filgotynib\/\"><span class=\"wp-block-navigation-item__label\">JAK (TOF\/BAR\/UPA\/FIL)<\/span><\/a><\/li><\/ul><\/nav>","protected":false},"excerpt":{"rendered":"<p>Monitorowanie bezpiecze\u0144stwa i bada\u0144 kontrolnych przy lekach celowanych (w tym inhibitory JAK). Narz\u0119dzie wspieraj\u0105ce i edukacyjne. Nie zast\u0119puje decyzji klinicznych. Zobacz zasady bezpiecze\u0144stwa. Lista lek\u00f3w i checklisty<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":1008,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_bbp_topic_count":0,"_bbp_reply_count":0,"_bbp_total_topic_count":0,"_bbp_total_reply_count":0,"_bbp_voice_count":0,"_bbp_anonymous_reply_count":0,"_bbp_topic_count_hidden":0,"_bbp_reply_count_hidden":0,"_bbp_forum_subforum_count":0,"_kadence_starter_templates_imported_post":false,"_kad_post_transparent":"","_kad_post_title":"","_kad_post_layout":"","_kad_post_sidebar_id":"","_kad_post_content_style":"","_kad_post_vertical_padding":"","_kad_post_feature":"","_kad_post_feature_position":"","_kad_post_header":false,"_kad_post_footer":false,"_kad_post_classname":"","footnotes":""},"class_list":["post-1014","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/rheumanext.pl\/pl\/wp-json\/wp\/v2\/pages\/1014","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/rheumanext.pl\/pl\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/rheumanext.pl\/pl\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/rheumanext.pl\/pl\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/rheumanext.pl\/pl\/wp-json\/wp\/v2\/comments?post=1014"}],"version-history":[{"count":3,"href":"https:\/\/rheumanext.pl\/pl\/wp-json\/wp\/v2\/pages\/1014\/revisions"}],"predecessor-version":[{"id":1050,"href":"https:\/\/rheumanext.pl\/pl\/wp-json\/wp\/v2\/pages\/1014\/revisions\/1050"}],"up":[{"embeddable":true,"href":"https:\/\/rheumanext.pl\/pl\/wp-json\/wp\/v2\/pages\/1008"}],"wp:attachment":[{"href":"https:\/\/rheumanext.pl\/pl\/wp-json\/wp\/v2\/media?parent=1014"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}